emactuzumab   Click here for help

GtoPdb Ligand ID: 8944

Synonyms: RG7155 | RO5509554
Immunopharmacology Ligand
Compound class: Antibody
Comment: Emactuzumab is a humanized, IgG1κ anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibody, being investigated for its anti-cancer potential.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
Peptide sequence analysis using the heavy and light chain variable regions of emactuzumab reveals 100% matches to sequences 39 and 40 respectively from patent US20110165156 [2]. These two sequences belong to the clone named hMab 2F11-e7 (or simply 2F11) in the patent document.

In 2018 Roche terminated their emactuzumab development programme. In August 2020 they announced that they were licensing emactuzumab to Celleron Therapeutics who intent to progress the drug as a treatment for diffuse tenosynovial giant cell tumours (TGCT), for which Roche have alreaady published efficacy [7], TGCT is driven by cells that overproduce the CSF1 protein which attracts the macrophages that ultimately cause the inflammatory damage that characterises the disease.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Emactuzumab has progressed to Phase 2 clinical evaluation in patients with a range of advanced/metastatic solid tumours (as of November 2018). Click here to link to ClinicalTrials.gov's full list of emactuzumab trials.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01494688 A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors Phase 1 Interventional Hoffmann-La Roche Although emactuzumab reduced immunosuppressive tumour-associated macrophages in the tumours of trial participants, it showed no antitumor efficacy. The drug did however exhibit signs of benefit in a cohort of patients with TGCT in a dose-escalation and dose-expansion of the study. 1,3